Prostate Cancer Therapeutics Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion

Market Dynamics of Prostate Cancer Therapeutics Market Analysis

Growth Drivers

  • The growing prevalence of prostate cancer fuels the growth of the prostate cancer therapeutics market.
  • Biotechnological innovation in prostate cancer treatment drugs to drive the global market of prostate cancer therapeutics.

Restraints

  • Recurrent/Non-Responsive prostate cancer restrains the growth of the prostate cancer therapeutics market.  

Trends

  • Advancements in drugs for prostate cancer treatment drive the prostate cancer therapeutics market.

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

Prostate Cancer Therapeutics Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Regional and Country Analysis

Global Prostate Cancer Therapeutics Market Analysis 2026

Region / Country 2021 (A)2025 (A)2033 (P) CAGR
Globalxxxxxxxxxxxxxxxx
North Americaxxxxxxxxxxxxxxxx
United Statesxxxxxxxxxxxxxxxx
Canadaxxxxxxxxxxxxxxxx
Mexicoxxxxxxxxxxxxxxxx
Europexxxxxxxxxxxxxxxx
United Kingdomxxxxxxxxxxxxxxxx
Francexxxxxxxxxxxxxxxx
Germanyxxxxxxxxxxxxxxxx
Italyxxxxxxxxxxxxxxxx
Russiaxxxxxxxxxxxxxxxx
Spainxxxxxxxxxxxxxxxx
Swedenxxxxxxxxxxxxxxxx
Denmarkxxxxxxxxxxxxxxxx
Switzerlandxxxxxxxxxxxxxxxx
Luxembourgxxxxxxxxxxxxxxxx
Rest of Europexxxxxxxxxxxxxxxx
Asia Pacificxxxxxxxxxxxxxxxx
Chinaxxxxxxxxxxxxxxxx
Japanxxxxxxxxxxxxxxxx
South Koreaxxxxxxxxxxxxxxxx
Indiaxxxxxxxxxxxxxxxx
Australiaxxxxxxxxxxxxxxxx
Singaporexxxxxxxxxxxxxxxx
Taiwanxxxxxxxxxxxxxxxx
South East Asiaxxxxxxxxxxxxxxxx
Rest of APACxxxxxxxxxxxxxxxx
South Americaxxxxxxxxxxxxxxxx
Brazilxxxxxxxxxxxxxxxx
Argentinaxxxxxxxxxxxxxxxx
Colombiaxxxxxxxxxxxxxxxx
Peruxxxxxxxxxxxxxxxx
Chilexxxxxxxxxxxxxxxx
Rest of South Americaxxxxxxxxxxxxxxxx
Middle Eastxxxxxxxxxxxxxxxx
Saudi Arabiaxxxxxxxxxxxxxxxx
Turkeyxxxxxxxxxxxxxxxx
UAExxxxxxxxxxxxxxxx
Egyptxxxxxxxxxxxxxxxx
Qatarxxxxxxxxxxxxxxxx
Rest of Middle Eastxxxxxxxxxxxxxxxx
Africaxxxxxxxxxxxxxxxx
East Africaxxxxxxxxxxxxxxxx
West Africaxxxxxxxxxxxxxxxx
North Africaxxxxxxxxxxxxxxxx
South Africaxxxxxxxxxxxxxxxx

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis

Segment Performance in The Prostate Cancer Therapeutics Market Treatment Therapy Segment Analysis It is predicted that during the forecast period 2024 to 2031, the Targeted Therapy Segment to witness significant growth at the fastest CAGR of XX%. Targeted therapy for prostate cancer is in high demand due to its precision approach, personalized treatment potential, and improved efficacy compared to traditional methods. By specifically targeting molecular alterations driving cancer growth, these therapies offer better outcomes with potentially fewer side effects. They also provide hope for patients who have developed resistance to standard treatments. With growing clinical evidence, regulatory approvals, and ongoing research advancements, targeted therapies continue to gain traction as a vital component of prostate cancer treatment strategies. Researchers and scientists are investigating a wide variety of novel targets in the rapidly growing area of targeted therapy in cancer. The accessibility of targeted therapy segment expansion is supported by the establishment of patient aid programs. For instance, in 2022 the FDA approved a groundbreaking targeted therapy for advanced prostate cancer called lutetium Lu 177 PSMA-617, marketed under the name “Lu 177 PSMA-617”. This therapy targets prostate-specific membrane antigen (PSMA), a protein found in high levels in prostate cancer cells, delivering radiation directly to the cancer cells while sparing healthy tissue. Source:(https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer) Its approval marked a significant shift in prostate cancer treatment, offering new hope for patients with advanced disease.

• By Chemotherapy Prostate Cancer Therapeutics Market Analysis
XX
• By Chemotherapy Market Size 2025
XX %
CAGR
Locked · Full data in paid report
o Systemic Therapy Prostate Cancer Therapeutics Market Analysis
XX
o Systemic Therapy Market Size 2025
XX %
CAGR
Locked · Full data in paid report
o Regional Chemotherapy Prostate Cancer Therapeutics Market Analysis
XX
o Regional Chemotherapy Market Size 2025
XX %
CAGR
Locked · Full data in paid report
• Hormonal Therapy Prostate Cancer Therapeutics Market Analysis
XX
• Hormonal Therapy Market Size 2025
XX %
CAGR
Locked · Full data in paid report
o Anti-Androgens Prostate Cancer Therapeutics Market Analysis
XX
o Anti-Androgens Market Size 2025
XX %
CAGR
Locked · Full data in paid report
o LHRH Antagonists Prostate Cancer Therapeutics Market Analysis
XX
o LHRH Antagonists Market Size 2025
XX %
CAGR
Locked · Full data in paid report
o LHRH Analogs Prostate Cancer Therapeutics Market Analysis
XX
o LHRH Analogs Market Size 2025
XX %
CAGR
Locked · Full data in paid report
• Targeted Therapy Prostate Cancer Therapeutics Market Analysis
XX
• Targeted Therapy Market Size 2025
XX %
CAGR
Locked · Full data in paid report
o Apoptosis-inducing drugs Prostate Cancer Therapeutics Market Analysis
XX
o Apoptosis-inducing drugs Market Size 2025
XX %
CAGR
Locked · Full data in paid report
o Angiogenesis inhibitor Prostate Cancer Therapeutics Market Analysis
XX
o Angiogenesis inhibitor Market Size 2025
XX %
CAGR
Locked · Full data in paid report
o Signal transduction inhibitor Prostate Cancer Therapeutics Market Analysis
XX
o Signal transduction inhibitor Market Size 2025
XX %
CAGR
Locked · Full data in paid report
• Immunotherapy Prostate Cancer Therapeutics Market Analysis
XX
• Immunotherapy Market Size 2025
XX %
CAGR
Locked · Full data in paid report
o Vaccines Prostate Cancer Therapeutics Market Analysis
XX
o Vaccines Market Size 2025
XX %
CAGR
Locked · Full data in paid report

Market size by (Illustrative, 2025)
Share distribution (2025)

Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.

To learn more about market share and segmentation, request the free sample pages.

Competitor Analysis

Competitive Landscape: The Prostate Cancer Therapeutics Market

The competitive landscape of the Prostate Cancer Therapeutics market is highly segmented, with several players competing for market share. Mergers and acquisitions along with investments and government partnership are the key strategies adopted by the players in the Prostate Cancer Therapeutics Market. Continuous innovation, strategic partnerships, and product development are essential for maintaining competitiveness and leadership in the Prostate Cancer Therapeutics market.
Some of the major players operating in the global prostate cancer market include Pfizer, Ipsen Pharma, Takeda Pharmaceutical Company Ltd, Johnson & Johnson, Indevus Pharmaceuticals, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG, Sanofi S.A., Tolmar Inc., Bayer AG, Astellas Pharma Inc., Dendreon Pharmaceuticals LLC, and Novartis AG.
For instance, in June 2021, Bayer, a Germany-based pharmaceutics company acquired Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc. for an undisclosed amount. With this acquisition, Bayer will gain exclusive access to a specialized alpha radionuclide investigational drug built on actinium-225 and a small molecule aimed against prostate-specific membrane antigens. PSMA Therapeutics Inc. is a US-based company that specializes in prostate-specific membrane antigen research and Noria Therapeutics Inc. is a radiotherapy firm focused on creating alpha-emitting radiopharmaceuticals for targeted therapeutic and imaging applications in oncology.
Source:(https://www.bayer.com/media/en-us/bayer-acquires-noria-and-psma-therapeutics-to-expand-portfolio-in-prostate-cancer/)
 

Click any bar or cell to request the full company profile
Top Companies (In no particular order)2022 (A)2023 (A)2024 (A)2025 (A)
Bristol-Myers Squibb Company••• ••• ••• •••
EUSA Pharma••• ••• ••• •••
Inc.••• ••• ••• •••
OSI Retail Pharmacy••• ••• ••• •••
Inc.••• ••• ••• •••
Paladin Labs Inc.••• ••• ••• •••
Amgen Inc.••• ••• ••• •••
Cell Genesys Inc.••• ••• ••• •••
Spectrum Retail Pharmacy••• ••• ••• •••
Inc.••• ••• ••• •••
Indevus Retail Pharmacy Inc.••• ••• ••• •••
Medimmune••• ••• ••• •••
Dendreon Corporation••• ••• ••• •••
Genentech Inc.••• ••• ••• •••
Abbott Laboratories••• ••• ••• •••
GlaxoSmithKline Plc••• ••• ••• •••
Pfizer Inc.••• ••• ••• •••
Immunomedics••• ••• ••• •••
Inc.••• ••• ••• •••
Progenics Retail Pharmacy••• ••• ••• •••
Inc.••• ••• ••• •••
Takeda Pharmaceutical Company Limited••• ••• ••• •••
Sanofi-Aventis SA••• ••• ••• •••
F. Hoffmann-La Roche Ltd.••• ••• ••• •••
Novartis AG••• ••• ••• •••
AstraZeneca PLC••• ••• ••• •••

We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.

Request company profile for validation →

Report Scope & Analysis

According to Cognitive Market Research, The Prostate Cancer Therapeutics Market was USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031. 
North America held the major market share for more than XX% of the global revenue with a market size of USD XX  million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031.
The Asia Pacific region is the fastest-growing market with a CAGR of XX% from 2024 to 2031 and it is projected that it will grow at a CAGR of XX% in the future.
Europe accounted for a market share of over XX% of the global revenue with a market size of USD XX million.
Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
The Prostate Cancer Therapeutics Market held the highest market revenue share in 2024.
 

Introduction of The Prostate Cancer Therapeutics Market

Prostate cancer drugs are medications that prevent and treat prostate cancer. It is one of the most widespread forms of this disease, which occurs when cells in the male reproductive system’s walnut-shaped gland start dividing and growing uncontrollably. The organ produces semen that feeds and transports spermatozoa. Hormone therapy, chemotherapy, targeted treatment, and immunotherapy can be used as possible options against it.
There are two types of prostate cancer drugs which are hormone-sensitive prostate cancer (HSPC) and hormone-refractory prostate cancer (HRPC). HRPC is a type of prostate cancer that does not respond to therapy with hormones anymore including more recent ones. They consist of various kinds such as hormonal therapy, chemotherapy, immunotherapy, and targeted therapy and they may be found at hospitals or clinics among other places.
The rise during the forecast period can be attributed to the growing incidence of disease, old age population groups, emerging economics; advancement in medicines, research and development investment, precision medicines, and government-supportive rules and regulations. Major driving factors that could be an opportunity for the growing market can be precision medicine, clinical trials, biomarker-driven treatment, immunotherapy, targeted therapy, combination therapy, telemedicine, and digital health solutions.
 

Analyst Conclusion

With the help of the above study about the Prostate Cancer Therapeutics Market, it can be concluded that the market for Prostate Cancer Therapeutics worldwide is expected to develop significantly shortly. From the report, one can understand and infer the market dynamics, segmentations, status and trends, and key players in the market. It provides data regarding various topics such as market dimensions, prevailing trends, competitive landscape, and the outlook for prospective expansion. This allows the reader to understand and access reliable data about the market and industry.


 

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst
LinkedIn Profile Book a free Consultation

Frequently Asked Questions

Prostate Cancer Therapeutics Market Analysis market size and growth rate is provided in the report covering 2021-2025 historical and 2025-2033 forecast data.
Major factors including drivers, restraints, opportunities and challenges are analyzed with detailed insights.
Top manufacturers Bristol-Myers Squibb Company, EUSA Pharma, Inc., OSI Retail Pharmacy, Inc., Paladin Labs Inc., Amgen Inc., Cell Genesys Inc., Spectrum Retail Pharmacy, Inc., Indevus Retail Pharmacy Inc., Medimmune, Dendreon Corporation, Genentech Inc., Abbott Laboratories, GlaxoSmithKline Plc, Pfizer Inc., Immunomedics, Inc., Progenics Retail Pharmacy, Inc., Takeda Pharmaceutical Company Limited, Sanofi-Aventis SA, F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca PLC and others are profiled in the report.
Segments include Treatment Therapy , Distribution and additional sub-segments.
Regional analysis covers all major markets. The report identifies the dominant region and provides country-level data.
Sample pages can be obtained on demand from the website. 24/7 chat support and direct call services are available.

★ Reviews

Rate this report

Prostate Cancer Therapeutics Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
Treatment Therapy • By Chemotherapy, o Systemic Therapy, o Regional Chemotherapy, • Hormonal Therapy, o Anti-Androgens, o LHRH Antagonists, o LHRH Analogs, • Targeted Therapy, o Apoptosis-inducing drugs, o Angiogenesis inhibitor, o Signal transduction inhibitor, • Immunotherapy, o Vaccines
Distribution Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
List of CompetitorsBristol-Myers Squibb Company, EUSA Pharma, Inc., OSI Retail Pharmacy, Inc., Paladin Labs Inc., Amgen Inc., Cell Genesys Inc., Spectrum Retail Pharmacy, Inc., Indevus Retail Pharmacy Inc., Medimmune, Dendreon Corporation, Genentech Inc., Abbott Laboratories, GlaxoSmithKline Plc, Pfizer Inc., Immunomedics, Inc., Progenics Retail Pharmacy, Inc., Takeda Pharmaceutical Company Limited, Sanofi-Aventis SA, F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca PLC

  • Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))

    • 1.1 Top Competitors Analysis
      • 1.1.1 Global Prostate Cancer Therapeutics Market Analysis by Key Players
      • 1.1.2 Segment Market Analysis by Key Players
      • 1.1.3 Top Players Ranking 2024
      • 1.1.4 New Product Launch Analysis
      • 1.1.5 Industry Mergers and Acquisition Analysis
    • 1.2 Company Profile (Data Subject to Availability) Sample Format
      • 1.2.1 Bristol-Myers Squibb Company
        • 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.1.2 Business Overview
        • 1.2.1.3 Financials (Subject to data availability)
        • 1.2.1.4 R&D Investment (Subject to data availability)
        • 1.2.1.5 Product Types Specification
        • 1.2.1.6 Business Strategy
        • 1.2.1.7 Recent Developments
        • 1.2.1.8 Management Change
        • 1.2.1.9 S.W.O.T Analysis
      • 1.2.2 EUSA Pharma
        • 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.2.2 Business Overview
        • 1.2.2.3 Financials (Subject to data availability)
        • 1.2.2.4 R&D Investment (Subject to data availability)
        • 1.2.2.5 Product Types Specification
        • 1.2.2.6 Business Strategy
        • 1.2.2.7 Recent Developments
        • 1.2.2.8 Management Change
        • 1.2.2.9 S.W.O.T Analysis
      • 1.2.3 Inc.
        • 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.3.2 Business Overview
        • 1.2.3.3 Financials (Subject to data availability)
        • 1.2.3.4 R&D Investment (Subject to data availability)
        • 1.2.3.5 Product Types Specification
        • 1.2.3.6 Business Strategy
        • 1.2.3.7 Recent Developments
        • 1.2.3.8 Management Change
        • 1.2.3.9 S.W.O.T Analysis
      • 1.2.4 OSI Retail Pharmacy
        • 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.4.2 Business Overview
        • 1.2.4.3 Financials (Subject to data availability)
        • 1.2.4.4 R&D Investment (Subject to data availability)
        • 1.2.4.5 Product Types Specification
        • 1.2.4.6 Business Strategy
        • 1.2.4.7 Recent Developments
        • 1.2.4.8 Management Change
        • 1.2.4.9 S.W.O.T Analysis
      • 1.2.5 Inc.
        • 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.5.2 Business Overview
        • 1.2.5.3 Financials (Subject to data availability)
        • 1.2.5.4 R&D Investment (Subject to data availability)
        • 1.2.5.5 Product Types Specification
        • 1.2.5.6 Business Strategy
        • 1.2.5.7 Recent Developments
        • 1.2.5.8 Management Change
        • 1.2.5.9 S.W.O.T Analysis
      • 1.2.6 Paladin Labs Inc.
        • 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.6.2 Business Overview
        • 1.2.6.3 Financials (Subject to data availability)
        • 1.2.6.4 R&D Investment (Subject to data availability)
        • 1.2.6.5 Product Types Specification
        • 1.2.6.6 Business Strategy
        • 1.2.6.7 Recent Developments
        • 1.2.6.8 Management Change
        • 1.2.6.9 S.W.O.T Analysis
      • 1.2.7 Amgen Inc.
        • 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.7.2 Business Overview
        • 1.2.7.3 Financials (Subject to data availability)
        • 1.2.7.4 R&D Investment (Subject to data availability)
        • 1.2.7.5 Product Types Specification
        • 1.2.7.6 Business Strategy
        • 1.2.7.7 Recent Developments
        • 1.2.7.8 Management Change
        • 1.2.7.9 S.W.O.T Analysis
      • 1.2.8 Cell Genesys Inc.
        • 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.8.2 Business Overview
        • 1.2.8.3 Financials (Subject to data availability)
        • 1.2.8.4 R&D Investment (Subject to data availability)
        • 1.2.8.5 Product Types Specification
        • 1.2.8.6 Business Strategy
        • 1.2.8.7 Recent Developments
        • 1.2.8.8 Management Change
        • 1.2.8.9 S.W.O.T Analysis
      • 1.2.9 Spectrum Retail Pharmacy
        • 1.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.9.2 Business Overview
        • 1.2.9.3 Financials (Subject to data availability)
        • 1.2.9.4 R&D Investment (Subject to data availability)
        • 1.2.9.5 Product Types Specification
        • 1.2.9.6 Business Strategy
        • 1.2.9.7 Recent Developments
        • 1.2.9.8 Management Change
        • 1.2.9.9 S.W.O.T Analysis
      • 1.2.10 Inc.
        • 1.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.10.2 Business Overview
        • 1.2.10.3 Financials (Subject to data availability)
        • 1.2.10.4 R&D Investment (Subject to data availability)
        • 1.2.10.5 Product Types Specification
        • 1.2.10.6 Business Strategy
        • 1.2.10.7 Recent Developments
        • 1.2.10.8 Management Change
        • 1.2.10.9 S.W.O.T Analysis
      • 1.2.11 Indevus Retail Pharmacy Inc.
        • 1.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.11.2 Business Overview
        • 1.2.11.3 Financials (Subject to data availability)
        • 1.2.11.4 R&D Investment (Subject to data availability)
        • 1.2.11.5 Product Types Specification
        • 1.2.11.6 Business Strategy
        • 1.2.11.7 Recent Developments
        • 1.2.11.8 Management Change
        • 1.2.11.9 S.W.O.T Analysis
      • 1.2.12 Medimmune
        • 1.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.12.2 Business Overview
        • 1.2.12.3 Financials (Subject to data availability)
        • 1.2.12.4 R&D Investment (Subject to data availability)
        • 1.2.12.5 Product Types Specification
        • 1.2.12.6 Business Strategy
        • 1.2.12.7 Recent Developments
        • 1.2.12.8 Management Change
        • 1.2.12.9 S.W.O.T Analysis
      • 1.2.13 Dendreon Corporation
        • 1.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.13.2 Business Overview
        • 1.2.13.3 Financials (Subject to data availability)
        • 1.2.13.4 R&D Investment (Subject to data availability)
        • 1.2.13.5 Product Types Specification
        • 1.2.13.6 Business Strategy
        • 1.2.13.7 Recent Developments
        • 1.2.13.8 Management Change
        • 1.2.13.9 S.W.O.T Analysis
      • 1.2.14 Genentech Inc.
        • 1.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.14.2 Business Overview
        • 1.2.14.3 Financials (Subject to data availability)
        • 1.2.14.4 R&D Investment (Subject to data availability)
        • 1.2.14.5 Product Types Specification
        • 1.2.14.6 Business Strategy
        • 1.2.14.7 Recent Developments
        • 1.2.14.8 Management Change
        • 1.2.14.9 S.W.O.T Analysis
      • 1.2.15 Abbott Laboratories
        • 1.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.15.2 Business Overview
        • 1.2.15.3 Financials (Subject to data availability)
        • 1.2.15.4 R&D Investment (Subject to data availability)
        • 1.2.15.5 Product Types Specification
        • 1.2.15.6 Business Strategy
        • 1.2.15.7 Recent Developments
        • 1.2.15.8 Management Change
        • 1.2.15.9 S.W.O.T Analysis
      • 1.2.16 GlaxoSmithKline Plc
        • 1.2.16.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.16.2 Business Overview
        • 1.2.16.3 Financials (Subject to data availability)
        • 1.2.16.4 R&D Investment (Subject to data availability)
        • 1.2.16.5 Product Types Specification
        • 1.2.16.6 Business Strategy
        • 1.2.16.7 Recent Developments
        • 1.2.16.8 Management Change
        • 1.2.16.9 S.W.O.T Analysis
      • 1.2.17 Pfizer Inc.
        • 1.2.17.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.17.2 Business Overview
        • 1.2.17.3 Financials (Subject to data availability)
        • 1.2.17.4 R&D Investment (Subject to data availability)
        • 1.2.17.5 Product Types Specification
        • 1.2.17.6 Business Strategy
        • 1.2.17.7 Recent Developments
        • 1.2.17.8 Management Change
        • 1.2.17.9 S.W.O.T Analysis
      • 1.2.18 Immunomedics
        • 1.2.18.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.18.2 Business Overview
        • 1.2.18.3 Financials (Subject to data availability)
        • 1.2.18.4 R&D Investment (Subject to data availability)
        • 1.2.18.5 Product Types Specification
        • 1.2.18.6 Business Strategy
        • 1.2.18.7 Recent Developments
        • 1.2.18.8 Management Change
        • 1.2.18.9 S.W.O.T Analysis
      • 1.2.19 Inc.
        • 1.2.19.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.19.2 Business Overview
        • 1.2.19.3 Financials (Subject to data availability)
        • 1.2.19.4 R&D Investment (Subject to data availability)
        • 1.2.19.5 Product Types Specification
        • 1.2.19.6 Business Strategy
        • 1.2.19.7 Recent Developments
        • 1.2.19.8 Management Change
        • 1.2.19.9 S.W.O.T Analysis
      • 1.2.20 Progenics Retail Pharmacy
        • 1.2.20.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.20.2 Business Overview
        • 1.2.20.3 Financials (Subject to data availability)
        • 1.2.20.4 R&D Investment (Subject to data availability)
        • 1.2.20.5 Product Types Specification
        • 1.2.20.6 Business Strategy
        • 1.2.20.7 Recent Developments
        • 1.2.20.8 Management Change
        • 1.2.20.9 S.W.O.T Analysis
      • 1.2.21 Inc.
        • 1.2.21.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.21.2 Business Overview
        • 1.2.21.3 Financials (Subject to data availability)
        • 1.2.21.4 R&D Investment (Subject to data availability)
        • 1.2.21.5 Product Types Specification
        • 1.2.21.6 Business Strategy
        • 1.2.21.7 Recent Developments
        • 1.2.21.8 Management Change
        • 1.2.21.9 S.W.O.T Analysis
      • 1.2.22 Takeda Pharmaceutical Company Limited
        • 1.2.22.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.22.2 Business Overview
        • 1.2.22.3 Financials (Subject to data availability)
        • 1.2.22.4 R&D Investment (Subject to data availability)
        • 1.2.22.5 Product Types Specification
        • 1.2.22.6 Business Strategy
        • 1.2.22.7 Recent Developments
        • 1.2.22.8 Management Change
        • 1.2.22.9 S.W.O.T Analysis
      • 1.2.23 Sanofi-Aventis SA
        • 1.2.23.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.23.2 Business Overview
        • 1.2.23.3 Financials (Subject to data availability)
        • 1.2.23.4 R&D Investment (Subject to data availability)
        • 1.2.23.5 Product Types Specification
        • 1.2.23.6 Business Strategy
        • 1.2.23.7 Recent Developments
        • 1.2.23.8 Management Change
        • 1.2.23.9 S.W.O.T Analysis
      • 1.2.24 F. Hoffmann-La Roche Ltd.
        • 1.2.24.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.24.2 Business Overview
        • 1.2.24.3 Financials (Subject to data availability)
        • 1.2.24.4 R&D Investment (Subject to data availability)
        • 1.2.24.5 Product Types Specification
        • 1.2.24.6 Business Strategy
        • 1.2.24.7 Recent Developments
        • 1.2.24.8 Management Change
        • 1.2.24.9 S.W.O.T Analysis
      • 1.2.25 Novartis AG
        • 1.2.25.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.25.2 Business Overview
        • 1.2.25.3 Financials (Subject to data availability)
        • 1.2.25.4 R&D Investment (Subject to data availability)
        • 1.2.25.5 Product Types Specification
        • 1.2.25.6 Business Strategy
        • 1.2.25.7 Recent Developments
        • 1.2.25.8 Management Change
        • 1.2.25.9 S.W.O.T Analysis
      • 1.2.26 AstraZeneca PLC
        • 1.2.26.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.26.2 Business Overview
        • 1.2.26.3 Financials (Subject to data availability)
        • 1.2.26.4 R&D Investment (Subject to data availability)
        • 1.2.26.5 Product Types Specification
        • 1.2.26.6 Business Strategy
        • 1.2.26.7 Recent Developments
        • 1.2.26.8 Management Change
        • 1.2.26.9 S.W.O.T Analysis

  • Chapter 2. Global Prostate Cancer Therapeutics Market Analysis

    • 2.1 Global Prostate Cancer Therapeutics Market Analysis
    • 2.2 Global Prostate Cancer Therapeutics Market Analysis by Region
    • 2.3 Global Prostate Cancer Therapeutics Market Analysis by Treatment Therapy
    • 2.4 Global Prostate Cancer Therapeutics Market Analysis by Distribution
    • 2.5 Global Prostate Cancer Therapeutics Market Analysis by Key Players

  • Chapter 3. North America Prostate Cancer Therapeutics Market Analysis

    • 3.1 North America Prostate Cancer Therapeutics Market Analysis
    • 3.2 North America Prostate Cancer Therapeutics Market Analysis by Country
    • 3.3 North America Prostate Cancer Therapeutics Market Analysis by Treatment Therapy
    • 3.4 North America Prostate Cancer Therapeutics Market Analysis by Distribution
    • 3.5 North America Prostate Cancer Therapeutics Market Analysis by Key Players

  • Chapter 4. Europe Prostate Cancer Therapeutics Market Analysis

    • 4.1 Europe Prostate Cancer Therapeutics Market Analysis
    • 4.2 Europe Prostate Cancer Therapeutics Market Analysis by Country
    • 4.3 Europe Prostate Cancer Therapeutics Market Analysis by Treatment Therapy
    • 4.4 Europe Prostate Cancer Therapeutics Market Analysis by Distribution
    • 4.5 Europe Prostate Cancer Therapeutics Market Analysis by Key Players

  • Chapter 5. Asia Pacific Prostate Cancer Therapeutics Market Analysis

    • 5.1 Asia Pacific Prostate Cancer Therapeutics Market Analysis
    • 5.2 Asia Pacific Prostate Cancer Therapeutics Market Analysis by Country
    • 5.3 Asia Pacific Prostate Cancer Therapeutics Market Analysis by Treatment Therapy
    • 5.4 Asia Pacific Prostate Cancer Therapeutics Market Analysis by Distribution
    • 5.5 Asia Pacific Prostate Cancer Therapeutics Market Analysis by Key Players

  • Chapter 6. South America Prostate Cancer Therapeutics Market Analysis

    • 6.1 South America Prostate Cancer Therapeutics Market Analysis
    • 6.2 South America Prostate Cancer Therapeutics Market Analysis by Country
    • 6.3 South America Prostate Cancer Therapeutics Market Analysis by Treatment Therapy
    • 6.4 South America Prostate Cancer Therapeutics Market Analysis by Distribution
    • 6.5 South America Prostate Cancer Therapeutics Market Analysis by Key Players

  • Chapter 7. Middle East Prostate Cancer Therapeutics Market Analysis

    • 7.1 Middle East Prostate Cancer Therapeutics Market Analysis
    • 7.2 Middle East Prostate Cancer Therapeutics Market Analysis by Country
    • 7.3 Middle East Prostate Cancer Therapeutics Market Analysis by Treatment Therapy
    • 7.4 Middle East Prostate Cancer Therapeutics Market Analysis by Distribution
    • 7.5 Middle East Prostate Cancer Therapeutics Market Analysis by Key Players

  • Chapter 8. Africa Prostate Cancer Therapeutics Market Analysis

    • 8.1 Africa Prostate Cancer Therapeutics Market Analysis
    • 8.2 Africa Prostate Cancer Therapeutics Market Analysis by Country
    • 8.3 Africa Prostate Cancer Therapeutics Market Analysis by Treatment Therapy
    • 8.4 Africa Prostate Cancer Therapeutics Market Analysis by Distribution
    • 8.5 Africa Prostate Cancer Therapeutics Market Analysis by Key Players

  • Chapter 9. Treatment Therapy Analysis

    • 9.1 • By Chemotherapy
      • 9.1.1 Global • By Chemotherapy Market
      • 9.1.2 Global • By Chemotherapy Market by Region
    • 9.2 o Systemic Therapy
      • 9.2.1 Global o Systemic Therapy Market
      • 9.2.2 Global o Systemic Therapy Market by Region
    • 9.3 o Regional Chemotherapy
      • 9.3.1 Global o Regional Chemotherapy Market
      • 9.3.2 Global o Regional Chemotherapy Market by Region
    • 9.4 • Hormonal Therapy
      • 9.4.1 Global • Hormonal Therapy Market
      • 9.4.2 Global • Hormonal Therapy Market by Region
    • 9.5 o Anti-Androgens
      • 9.5.1 Global o Anti-Androgens Market
      • 9.5.2 Global o Anti-Androgens Market by Region
    • 9.6 o LHRH Antagonists
      • 9.6.1 Global o LHRH Antagonists Market
      • 9.6.2 Global o LHRH Antagonists Market by Region
    • 9.7 o LHRH Analogs
      • 9.7.1 Global o LHRH Analogs Market
      • 9.7.2 Global o LHRH Analogs Market by Region
    • 9.8 • Targeted Therapy
      • 9.8.1 Global • Targeted Therapy Market
      • 9.8.2 Global • Targeted Therapy Market by Region
    • 9.9 o Apoptosis-inducing drugs
      • 9.9.1 Global o Apoptosis-inducing drugs Market
      • 9.9.2 Global o Apoptosis-inducing drugs Market by Region
    • 9.10 o Angiogenesis inhibitor
      • 9.10.1 Global o Angiogenesis inhibitor Market
      • 9.10.2 Global o Angiogenesis inhibitor Market by Region
    • 9.11 o Signal transduction inhibitor
      • 9.11.1 Global o Signal transduction inhibitor Market
      • 9.11.2 Global o Signal transduction inhibitor Market by Region
    • 9.12 • Immunotherapy
      • 9.12.1 Global • Immunotherapy Market
      • 9.12.2 Global • Immunotherapy Market by Region
    • 9.13 o Vaccines
      • 9.13.1 Global o Vaccines Market
      • 9.13.2 Global o Vaccines Market by Region

  • Chapter 10. Distribution Analysis

    • 10.1 Hospital Pharmacies
      • 10.1.1 Global Hospital Pharmacies Market
      • 10.1.2 Global Hospital Pharmacies Market by Region
    • 10.2 Online Pharmacies
      • 10.2.1 Global Online Pharmacies Market
      • 10.2.2 Global Online Pharmacies Market by Region
    • 10.3 Retail Pharmacies
      • 10.3.1 Global Retail Pharmacies Market
      • 10.3.2 Global Retail Pharmacies Market by Region

  • Chapter 11. Qualitative Analysis (Subject to Data Availability)

    • 11.1 Market Drivers
    • 11.2 Market Restraints
    • 11.3 Market Trends
    • 11.4 Market Opportunity
    • 11.5 Technological Road Map (Subject to Data Availability)
    • 11.6 Product Life Cycle (Subject to Data Availability)
    • 11.7 Customer and Buyer Behavior Analysis
      • 11.7.1 Digital Engagement, Customer Experience & Relationship Analysis
      • 11.7.2 Customer Buying Behavior & Purchase Decision Analysis
      • 11.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
      • 11.7.4 Pricing, Affordability & Value Perception Analysis
      • 11.7.5 Customer Segmentation & Demand Pattern Analysis
    • 11.8 PESTEL Analysis
      • 11.8.1 Political Factors
      • 11.8.2 Economic Factors
      • 11.8.3 Social Factors
      • 11.8.4 Technological Factors
      • 11.8.5 Legal Factors
      • 11.8.6 Environmental Factors
    • 11.9 Industrial Chain Analysis (Subject to Data Availability)
      • 11.9.1 Industry Chain Analysis
      • 11.9.2 Manufacturing Cost Analysis
      • 11.9.3 Supply Side Analysis
        • 11.9.3.1 Raw Material Analysis
        • 11.9.3.2 Raw Material Procurement Analysis
        • 11.9.3.3 Raw Material Price Trend Analysis
    • 11.10 Porter’s Five Forces Analysis
      • 11.10.1 Bargaining Power of Suppliers
      • 11.10.2 Bargaining Power of Buyers
      • 11.10.3 Threat of New Entrants
      • 11.10.4 Threat of Substitutes
      • 11.10.5 Degree of Competition
    • 11.11 Patent Analysis (Subject to Data Availability)
    • 11.12 ESG Analysis
    • 11.13 Geopolitical Outlook
      • 11.13.1 Global Power Realignment & Strategic Alliances
      • 11.13.2 Geopolitical Risk Landscape & Conflict Hotspots
      • 11.13.3 International Trade Relations & Market Access Environment
      • 11.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
      • 11.13.5 Supply Chain Resilience, Localization & Resource Nationalism
      • 11.13.6 Technology Sovereignty & Digital Geopolitics
      • 11.13.7 Strategic Implications for Investment, Growth & Market Entry
    • 11.14 AI & Market Transformation
      • 11.14.1 Competitive Landscape Disruption & Strategic Shifts
      • 11.14.2 AI-Driven Transformation of Industry Value Chain
      • 11.14.3 Evolution of Business Models & Revenue Streams
      • 11.14.4 AI-Driven Product, Service & Innovation Transformation
      • 11.14.5 Customer Behavior, AI Adoption & Future Market Evolution

  • Chapter 12. TOP 10 Country Analysis

    • 12.1 Country 1
    • 12.2 Country 2
    • 12.3 Country 3
    • 12.4 Country 4
    • 12.5 Country 5
    • 12.6 Country 6
    • 12.7 Country 7
    • 12.8 Country 8
    • 12.9 Country 9
    • 12.10 Country 10

  • Chapter 13. Research Findings

    • 13.1 Key Takeaways
    • 13.2 Analyst Point of View
    • 13.3 Assumptions and Acronyms

  • Chapter 14. Research Methodology and Sources

    • 14.1 Primary Data Collection
      • 14.1.1 Steps for Primary Data Collection
        • 14.1.1.1 Identification of KOL
      • 14.1.2 Backward Integration
      • 14.1.3 Forward Integration
      • 14.1.4 How Primary Research Help Us
      • 14.1.5 Modes of Primary Research
    • 14.2 Secondary Research
      • 14.2.1 How Secondary Research Help Us
      • 14.2.2 Sources of Secondary Research
    • 14.3 Data Validation
      • 14.3.1 Data Triangulation
    • 14.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Prostate Cancer Therapeutics Market Analysis Market analysis.

01

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

02

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

03

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

04

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

05

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics
Data Points Validated 10,400+
Expert Interviews 54
Countries Covered 39+
Company Profiles 26+
Forecast Accuracy (Historical) 94.2%
Analytical Coverage
Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Latest News about Prostate Cancer Therapeutics Market

In February 2023, Fusion Pharmaceuticals, a clinical-stage oncology corporation concentrated on designing next-generation targeted alpha therapies ("TATs") as precision therapies, acquired the investigational new drug application ("IND") for an ongoing Phase 2 clinical trial (the "TATCIST" trial) evaluating 225Ac-PSMA I&T, a small molecule targeting prostate-specific membrane antigen ("PSMA") expressed on prostate cancers from RadioMedix, Inc., a clinical-stage biotechnology corporation.
Source:(https://ir.fusionpharma.com/2023-02-13-Fusion-Pharmaceuticals-to-Acquire-Phase-2-Program-for-225Ac-PSMA-I-T,-a-Radiopharmaceutical-Targeting-Metastatic-Castrate-Resistant-Prostate-Cancer)

In March 2023, Pfizer, an American global biotechnology and pharmaceutical company, and Seagen Inc., a multinational biotechnology corporation, formed a definitive merger agreement under which Pfizer will obtain Seagen for USD 229 in cash per Seagen share for a total enterprise worth USD 43 billion.
Source:(https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invests-43-billion-battle-cancer)

Sources from the Pharma and Healthcare Industry

How We Serve You

The Three Pillars of End-to-End Market Research Services

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Prostate Cancer Therapeutics Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the prostate cancer therapeutics market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included
  • Buyer intent & sentiment analysis
  • Purchase cycle mapping
  • Price sensitivity research
  • Channel preference profiling
  • Competitive perception study
Most Requested
Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included
  • Ready syndicate report
  • Custom data scope & segmentation
  • Excel quantitative models
  • Board-ready PPT with key findings
  • Secure cloud portal access
Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included
  • Dedicated analyst assigned to you
  • Live walkthrough of findings
  • Strategic Q&A sessions
  • Go-to-market recommendations
  • NDA-protected engagement

Customize This Report

Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.